The Globe and Mail reports in its Friday, Nov. 3, edition that RBC Capital Markets analyst Andrew Wong continues to rate Nutrien "outperform." The Globe's David Leeder writes in the Eye On Equities column that Mr. Wong gave his share target a $5 trim to $80 (all figures U.S.). Analysts on average target the shares at $74.82. Mr. Wong says in a note: "We think Nutrien delivered a solid Q3 result that hit all the right notes -- potash improvement, retail margin recovery, and further capex discipline. We view shares as undervalued, implying a one to two times EV/EBITDA multiple discount to peers on the fertilizer business. We see more stable company and fertilizer market performance as the path to restoring investor confidence and a recovery in valuation." The Globe's Ian McGugan recommended waiting to buy Nutrien at a better price on May 20 when the shares were going for $61.95. The Globe reported on July 7 that Credit Suisse analyst Edlain Rodriguez has reiterated his "underperform" call on Nutrien. The shares could be had for $60. The Globe reported on May 9 and Aug. 1 that TD Cowen analyst Michael Tupholme rated Nutrien at "hold" and "buy." It was then worth $64.50 and $67.